Treating glioblastoma with a Ziopharm drug and IL-12 gene therapy

A phase 1 clinical trial in glioblastoma involving Ziopharm Oncology suggests that controlling the production of human IL-12 using gene therapy along with a drug "switch" could reduce inflammation while preserving promising anti-tumor effects.